IL310670A - Anti-related-to-receptor tyrosine kinase (ryk) antibodies and uses thereof - Google Patents

Anti-related-to-receptor tyrosine kinase (ryk) antibodies and uses thereof

Info

Publication number
IL310670A
IL310670A IL310670A IL31067024A IL310670A IL 310670 A IL310670 A IL 310670A IL 310670 A IL310670 A IL 310670A IL 31067024 A IL31067024 A IL 31067024A IL 310670 A IL310670 A IL 310670A
Authority
IL
Israel
Prior art keywords
ryk
seq
antibody
cdr
set forth
Prior art date
Application number
IL310670A
Other languages
English (en)
Hebrew (he)
Inventor
Thomas J Kipps
Ii George F Widhopf
Original Assignee
Univ California
Thomas J Kipps
Ii George F Widhopf
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California, Thomas J Kipps, Ii George F Widhopf filed Critical Univ California
Publication of IL310670A publication Critical patent/IL310670A/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/5759—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57557—Immunoassay; Biospecific binding assay; Materials therefor for cancer of other specific parts of the body, e.g. brain
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Oncology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
IL310670A 2021-08-18 2022-08-18 Anti-related-to-receptor tyrosine kinase (ryk) antibodies and uses thereof IL310670A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163234527P 2021-08-18 2021-08-18
PCT/US2022/075147 WO2023023600A1 (en) 2021-08-18 2022-08-18 Anti-related-to-receptor tyrosine kinase (ryk) antibodies and uses thereof

Publications (1)

Publication Number Publication Date
IL310670A true IL310670A (en) 2024-04-01

Family

ID=85241071

Family Applications (1)

Application Number Title Priority Date Filing Date
IL310670A IL310670A (en) 2021-08-18 2022-08-18 Anti-related-to-receptor tyrosine kinase (ryk) antibodies and uses thereof

Country Status (11)

Country Link
US (1) US20250027945A1 (https=)
EP (1) EP4387669A4 (https=)
JP (1) JP2024535691A (https=)
KR (1) KR20240046558A (https=)
CN (1) CN117979997A (https=)
AU (1) AU2022331476A1 (https=)
CA (1) CA3229528A1 (https=)
IL (1) IL310670A (https=)
MX (1) MX2024001979A (https=)
TW (1) TW202315894A (https=)
WO (1) WO2023023600A1 (https=)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR028424A1 (es) * 2000-05-10 2003-05-07 Bayer Corp Metodo para regular la angiogenesis utilizando proteina ryk
AU2003239248A1 (en) * 2002-06-07 2003-12-22 The Government Of The United States, As Represented By The Secretary Of The Department Of Health And Anti-cd30 stalk and anti-cd30 antibodies suitable for use in immunotoxins
CA2694055A1 (en) * 2007-08-01 2009-02-05 Glaxo Group Limited Novel antibodies
WO2017172733A1 (en) * 2016-03-28 2017-10-05 The Regents Of The University Of California Anti-ryk antibodies and methods of using the same

Also Published As

Publication number Publication date
MX2024001979A (es) 2024-07-09
WO2023023600A1 (en) 2023-02-23
US20250027945A1 (en) 2025-01-23
AU2022331476A1 (en) 2024-02-22
CA3229528A1 (en) 2023-02-23
EP4387669A4 (en) 2025-06-25
CN117979997A (zh) 2024-05-03
KR20240046558A (ko) 2024-04-09
JP2024535691A (ja) 2024-10-02
TW202315894A (zh) 2023-04-16
EP4387669A1 (en) 2024-06-26

Similar Documents

Publication Publication Date Title
RU2639553C2 (ru) Модуляция активации макрофагов
RU2013125457A (ru) Комбинация антител против с-мет
RU2014118773A (ru) Антитела к родственной раково-эмбриональному антигену молекуле клеточной адгезии (сеасам)
CN109320612A (zh) 抗her2抗体及其缀合物
RU2013108054A (ru) Антитела против а2 тенасцина с и способы их применения
RU2010116184A (ru) Новые антитела
CA2664327A1 (en) Method for detecting and treating skin disorders
CN112830969B (zh) 一种特异性结合人Claudin18.2的单克隆抗体及包含其的药物和试剂盒
WO2019062755A1 (en) BISPECIFIC ANTIBODIES DIRECTED AGAINST EGFR AND PD-1
WO2021249542A1 (en) Antibodies binding tnfr2 and uses thereof
US9611319B2 (en) Hybridoma clones and monoclonal antibodies to fibroblast growth factor 4
CN110546165B (zh) 抗-pd-l1-抗-tim-3双特异性抗体
Modjtahedi et al. Antitumor activity of combinations of antibodies directed against different epitopes on the extracellular domain of the human EGF receptor
CA3222040A1 (en) Anti-nkg2a antibodies and compositions
AU2003295601B2 (en) Autocrine growth factor receptor antibodies and methods
RU2017134042A (ru) ДИМЕРЫ SCFV-FC, КОТОРЫЕ СВЯЗЫВАЮТСЯ С ТРАНСФОРМИРУЮЩИМ ФАКТОРОМ РОСТА β1 С ВЫСОКОЙ АФФИННОСТЬЮ, АВИДНОСТЬЮ И СПЕЦИФИЧНОСТЬЮ
IL310684A (en) Membrane with biodegradable polymer
EP3524625A1 (en) Antibody against alpha-11 integrin and its use
IL310670A (en) Anti-related-to-receptor tyrosine kinase (ryk) antibodies and uses thereof
WO2025261506A1 (zh) 抗Nectin-4抗体以及其用途
US20260092116A1 (en) B7h3/pdl1 bispecific antibody, and pharmaceutical composition comprising same and use thereof
KR102312922B1 (ko) Tie2와 결합을 유도하는 항 Ang2 항체
WO2023221935A1 (zh) 结合pd-l1和cldn18.2的抗体及其用途
KR20150014077A (ko) 항 Ang2 항체
JP2024535691A5 (https=)